Hani Gabra
Founder chez Papyrus Therapeutics, Inc.
Profil
Hani Gabra is the founder of Papyrus Therapeutics, Inc. He is currently a Professor at Imperial College London.
He previously worked as the Director of Clinical Development at BerGenBio ASA from 2021 to 2022 and as the Vice President of Early Clinical Development at AstraZeneca PLC.
Postes actifs de Hani Gabra
Sociétés | Poste | Début |
---|---|---|
Imperial College London | Corporate Officer/Principal | - |
Papyrus Therapeutics, Inc.
Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Founder | - |
Anciens postes connus de Hani Gabra
Sociétés | Poste | Fin |
---|---|---|
BERGENBIO ASA | Chief Tech/Sci/R&D Officer | - |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
ASTRAZENECA PLC | Health Technology |
BERGENBIO ASA | Health Technology |
Entreprise privées | 1 |
---|---|
Papyrus Therapeutics, Inc.
Papyrus Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation. | Commercial Services |